Skip to main content
Premium Trial:

Request an Annual Quote

Maxygen Signs Research Agreement with NCI, Files For Second Stock Offering



EDWOOD CITY, Calif.--Maxygen announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute for pharmaceutical protein development. In the three-year deal, the company will apply its MolecularBreed-ing directed evolution technologies to the development of novel protein pharmaceuticals for cancer treatments. NCI will provide expertise in characterizing and evaluating the proteins for therapeutic potential. The specific target proteins and indications were not disclosed.

Separately, Maxygen filed with the US Securities and Exchange Commission to sell 1.5 million shares of common stock in what will be its second public offering. Maxygen went public last December with an offering of 6.9 million shares at $16 each, resulting in net proceeds of $102 million.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.